Innovating Works
HORIZON-HLTH-2024-DISEASE-17-01
Pandemic preparedness and response: Maintaining and enhancing the...
Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
Sólo fondo perdido 0 €
European
This call is closed This line is already closed so you can't apply. It closed last day 30-05-2024.
An upcoming call for this aid is expected, the exact start date of call is not yet clear.
Hace más de 15 mes(es) del cierre y aún no tenemos información sobre los proyectos financiados, no parece que se vaya a publicar esta información.
Presentation: Consortium Consortium: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Minimum number of participants.
This aid finances Proyectos:

Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

Investments in research and innovation on pandemic preparedness are balanced and better co-ordinated along the whole research continuum from basic research, over pre-clinical research to clinical research;Research funders, policymakers and the research community dispose of an enhanced research and innovation framework for the European partnership for pandemic preparedness, including the Partnership’s objectives, governance and ways of working/operationalisation;Research funders, policymakers and the research community are aligned towards common objectives and have a common understanding of the long-term Strategic Research and Innovation Agenda for the Partnership;Research funders, policymakers and the research community work towards a valued network of clinical trial sites that has the capacity to implement well-... see more

Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

Investments in research and innovation on pandemic preparedness are balanced and better co-ordinated along the whole research continuum from basic research, over pre-clinical research to clinical research;Research funders, policymakers and the research community dispose of an enhanced research and innovation framework for the European partnership for pandemic preparedness, including the Partnership’s objectives, governance and ways of working/operationalisation;Research funders, policymakers and the research community are aligned towards common objectives and have a common understanding of the long-term Strategic Research and Innovation Agenda for the Partnership;Research funders, policymakers and the research community work towards a valued network of clinical trial sites that has the capacity to implement well-coordinated large-scale multi-country quality trials in different target populations, which are able to smoothly transition to public health interventions relevant for cross-border health threats in response to a public health emergency;Healthcare providers, European and international stakeholders engage with an extended number of EU-wide appropriate partners through the research and innovation framework for the partnership. Scope:The COVID-19 pandemic illustrated how unilateral research initiatives may lead to a fragmented research landscape, with substantial room for efficiency gains in the development of the highly needed evidence to guide policy actions when facing an emergency. A coordination and support action[1] is working towards improving the EU’s preparedness to predict and respond to emerging infectious health threats by better coordinating funding for research and innovation at EU, national (and regional) level towards common objectives and an agreed Strategic Research and Innovation Agenda. This work should be complemented by efforts towards establishing, maintaining and enhancing a network of ever-warm clinical trials sites and infrastructures for clinical research, ready to be pivoted in case of a pandemic or epidemic episode. In addition, this work should be extended to additional partners, primarily from the EU and Horizon Europe associated countries. Participation from widening countries should be ensured, promoting an inclusive approach in the design and governance of the partnership.

The partnership will contribute to building a coherent European Research Area (ERA), enabling Member States, Associated Countries and the European Commission to rapidly and jointly support research and innovation in pandemic preparedness.

The Partnership is expected to continue to build on existing pandemic preparedness networks and research infrastructures and work in synergy with the Health Emergency Preparedness and Response Authority (HERA).

Proposals should include all of the following activities:

Provide administrative and organisational support to prepare, ensure a smooth start and transition towards the European partnership for pandemic preparedness that will eventually take over these tasks;Actively engage with relevant stakeholders and initiatives in the area of pandemic preparedness, ensuring collaboration and coordination, and avoiding duplication; e.g. the Global Health EDCTP3 Joint Undertaking, GloPID-R, WHO R&D blueprint, ACT Accelerator, etc.;Implement strong communication and dissemination activities at EU level and in Member States and Associated Countries, on the purpose, activities and outputs of the European partnership for pandemic preparedness, ensuring a continuous dialogue, both outside and during epidemic/pandemic episodes;As relevant, apply a cross-cutting, interdisciplinary One Health approach. This topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.

[1] Project BE READY / grant agreement number 101057795, funded under topic HORIZON-HLTH-2021-DISEASE-04-06 "Building a European partnership for pandemic preparedness".

see less

Temáticas Obligatorias del proyecto: Temática principal: Biological weapons (anthrax botulism…) Surveillance Mosquito Tick Veterinary medicine and infectious diseases in ani Transmission mechanism Transmission Helminths Smallpox Prions Clinical trials Statistics in clinical trials Phase III Clinical information Virology Chikingunya Influenza Emerging Epidemics Fungi Clinical research Clinical development Phase III Social sciences and humanities Protozoa Crimean Congo Haemorrhagic Fever Statistics in clinical trials Phase IV Dengue Prevention and treatment of infection by pathogens Interventional clinical trials Severe acute respiratory syndrome Bacteriology Microbiology Pathogen agents Cohort studies Disease control Public health and epidemiology Drug development clinical phases Drug development late phases Clinical data Clinical targets Vector control Hepatitis Statistics in clinical trials Phase II Clinical development Phase II Viral Haemorrhagic Fevers Preparedness Bacteria Infectious diseases Clinical development Phase I SARS Virulence Viruses West Nile Statistics in clinical trials Phase I Biological weapons Veterinary medicine and infectious diseases in animals Chikungunya Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Clinical Trials Epidemiology Infectious Diseases Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I

Consortium characteristics

Scope European : The aid is European, you can apply to this line any company that is part of the European Community.
Tipo y tamaño de organizaciones: The necessary consortium design for the processing of this aid needs:

characteristics of the Proyecto

Requisitos de diseño por participante: *Presupuesto para cada participante en el proyecto
Requisitos técnicos: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
Financial Chapters: The chapters of financing expenses for this line are:
Personnel costs.
Expenses related to personnel working directly on the project are based on actual hours spent, based on company costs, and fixed ratios for certain employees, such as the company's owners.
Subcontracting costs.
Payments to external third parties to perform specific tasks that cannot be performed by the project beneficiaries.
Purchase costs.
They include the acquisition of equipment, amortization, material, licenses or other goods and services necessary for the execution of the project
Other cost categories.
Miscellaneous expenses such as financial costs, audit certificates or participation in events not covered by other categories
Indirect costs.
Overhead costs not directly assignable to the project (such as electricity, rent, or office space), calculated as a fixed 25% of eligible direct costs (excluding subcontracting).
Madurez tecnológica: The processing of this aid requires a minimum technological level in the project of TRL 9:. En esta fase la innovación está en su fase final y es operable en un sin número de condiciones operativas, está probada y disponible para su comercialización y/o producción disponible para la sociedad. Entrega de producto o tecnología para producción en serie y comercialización. + info.
TRL esperado:

Characteristics of financing

Intensidad de la ayuda: Sólo fondo perdido + info
Lost Fund:
For the eligible budget, the intensity of the aid in the form of a lost fund may reach as minimum a 100%.
The funding rate for CSA projects is 100 % of the eligible costs for all types of organizations. The funding rate for CSA projects is 100 % of the eligible costs for all types of organizations.
Guarantees:
does not require guarantees
No existen condiciones financieras para el beneficiario.

Additional information about the call

incentive effect: Esta ayuda no tiene efecto incentivador. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
non -competitive competitive Very competitive
We do not know the total budget of the line
minimis: Esta línea de financiación NO considera una “ayuda de minimis”. You can consult the regulations here.
Certificado DNSH: Los proyectos presentados a esta línea deben de certificarse para demostrar que no causan perjuicio al medio ambiente. + info

other advantages

SME seal: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
HORIZON-HLTH-2024-DISEASE-17 Pandemic preparedness and response: Maintaining and enhancing the preparatory work for a co-funded European partnership for pandemic preparedness Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Sin info.
HORIZON-HLTH-2024-DISEASE-13-01 Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD)
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada does 9 months | next call scheduled for the month of
HORIZON-HLTH-2024-DISEASE-12-01 European partnership for pandemic preparedness
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada does 9 months | next call scheduled for the month of
HORIZON-HLTH-2024-DISEASE-09-01 European Partnership: One Health Anti-Microbial Resistance
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada does 11 months | next call scheduled for the month of
HORIZON-HLTH-2024-DISEASE-17-01 Pandemic preparedness and response: Maintaining and enhancing the preparatory work for a co-funded European partnership for pandemic preparedness
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada does 1 year | next call scheduled for the month of
HORIZON-HLTH-2024-DISEASE-08-20 Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada does 1 year | next call scheduled for the month of